RecruitingPhase 1NCT06940440
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TuHURA Biosciences, Inc.
- Principal Investigator
- Andrew S Brohl, MDCollaborator
- Intervention
- IFx-Hu2.0(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (2)
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06940440 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison
- RECRUITINGPHASE1, PHASE2NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerNational Cancer Institute (NCI)